Here are the Form 4 insider transactions from Mangoceuticals, Inc. (MGRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGRX filings page.
Mangoceuticals, Inc. (MGRX) reported that 2,000,000 shares were issuable to Chief Executive Officer, director and ten-percent owner Jacob D. Cohen as a bonus on July 28, 2026, in lieu of a change-of-control payment otherwise due under his employment agreement. Cohen transferred 2,000,000 shares to The Tiger Cub Trust, a ten-percent owner he controls, on August 11, 2026, and 500,000 shares on September 30, 2025; the transfers did not change beneficial ownership. A Convertible Promissory Note was paid in full on December 19, 2025; it was associated with 56,023 underlying common shares and a 1.785 conversion price per share.
Mangoceuticals, Inc. CFO Eugene M. Johnston received a grant of 100,000 common shares on July 28, 2026, at a reported price of $0.0000 per share. The shares were issued in consideration for services rendered as CFO. Johnston reported direct holdings of 220,000 common shares after the grant.
Mangoceuticals, Inc. director Alex P. Hamilton acquired 100,000 shares of Common Stock on July 28, 2026, as an award for services rendered as a member of the Board of Directors. Alex P. Hamilton's reported direct holdings after the award were 101,667 shares. The reported transaction price was 0.0000 per share.
Mangoceuticals, Inc. Chief Executive Officer Jacob D. Cohen reported several compensation and financing-related transactions. He received stock options for 2,000,000 shares of common stock at an exercise price of $2.30 per share, expiring in 2035, with vesting over 18 months and acceleration on certain terminations or a change of control. He was also granted 500,000 shares of common stock as a discretionary bonus for services in 2025.
In addition, a prior $100,000 promissory note held by The Tiger Cub Trust, which is beneficially owned by Cohen as trustee, was amended into a convertible promissory note with a conversion price of $1.785 per share and 18% annual interest, and Tiger Cub received warrants to purchase 50,000 shares at $1.85 per share. Cohen reported bona fide gifts totaling 400,000 shares of common stock transferred to The Tiger Cub Trust, which the footnotes state did not change his beneficial ownership.
MANGOCEUTICALS, INC. Chief Executive Officer Jacob D. Cohen reported an option repricing approved by the Board and its Compensation Committee. On the effective date, existing stock options covering 50,000, 83,333 and 2,000,000 shares of common stock were surrendered to the company and replaced on a one-for-one basis.
The replacement options cover the same total number of underlying shares but now carry a new exercise price of $0.45 per share, which the company states exceeded the Nasdaq closing price on the effective date. All other terms of the options, including prior vesting schedules, remain unchanged. Following these changes, Cohen also reports direct holdings of 200,000 and 605,000 shares of common stock.
Mangoceuticals, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/15/2025, the CFO sold 3,333 shares of the company’s common stock at a price of $1.1653 per share. After this sale, the CFO beneficially owned 120,000 shares, held directly. The filing reflects a routine update of the officer’s ownership position and does not list any derivative securities transactions.
Mangoceuticals, Inc. director reports stock sale in Form 4 filing. A board member of Mangoceuticals, Inc. (MGRX) disclosed the sale of 125,000 shares of common stock on 11/19/2025, reported under transaction code "S" for a sale. The weighted average sale price was $1.223 per share.
These shares were sold in multiple trades at prices ranging from $1.195 to $1.2465 per share. Following this transaction, the reporting person beneficially owns 3,334 shares of Mangoceuticals common stock in direct ownership.